Spots Global Cancer Trial Database for Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)
Official Title: A Phase 1 and Phase 2 Study of Lenalidomide (Revlimid) in Combination With Cyclophosphamide (Endoxan) and Prednison (REP) in Relapsed/Refractory Multiple Myeloma
Study ID: NCT01352338
Conditions
Study Description
Brief Summary: Study Phase: phase 1 and phase 2 Objective: Evaluation of the effect of lenalidomide, cyclophophamide and prednisone (REP) in patients with relapsed multiple myeloma previously treated with lenalidomide Study design: prospective, multicenter, non-randomized
Detailed Description: The REPEAT-study is a prospective, multicenter, non-randomized phase 1 and phase 2 study in which we evaluate the effect of lenalidomide, cyclophosphamide and prednisone (REP-therapy) in patients with relapsed multiple myeloma, previously treated with lenalidomide and refractory to lenalidomide monotherapy.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Antonius Ziekenhuis Nieuwegein, Nieuwegein, Utrecht, Netherlands
VU Medical Center, Amsterdam, , Netherlands
UMC Utrecht, Utrecht, , Netherlands
Contact Details
Name: Dr. N.C.W.J. Donk, van de, MD PhD
Affiliation: UMC Utrecht
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
